Fennec Pharmaceut…
USUSDFennec Pharmaceuticals Inc (TO:FRX) — Biotechnology: Biological Products (No Diagnostic Substances). Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О Компании
- Сайт
- fennecpharma.com
- Взаимодействие с Инвесторами
- investors.fennecpharma.com/
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Штаб-Квартира
- RESEARCH TRIANGLE PARK, United States
- Генеральный Директор
- Jeffrey S. Hackman
- Сотрудники
- 35
- На Бирже с
- 12.06.2001 (TO:FRX)
- Акций в Обращении
- 35.07 млн на 2026-08-11
- Свободное Обращение
- 19.88 млн
- Рыночная Капитализация
- 375.57 млн USD
- Инсайдеры
- 14.13%
- Институциональные Инвесторы
- 54.24%
- Отрасль (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- убыток
- FCF
- 3.92 млн USD
- Долг
- 19.4 млн USDденег больше, чем долга
- Прибыль и FCF — за 12 месяцев до 30.06.2026 года (последний отчет компании).
- NAV
Описание
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Крупнейшие Держатели
| Держатель | Доля | Акции | Дата Отчета |
|---|---|---|---|
| Rosalind Advisors, Inc. | 9.07% | 3.19 млн | 2026-06-30 |
| AIGH Capital Management… | 7.07% | 2.49 млн | 2026-06-30 |
| Solas Capital Management… | 5.38% | 1.89 млн | 2026-06-30 |
| Blackrock Inc. | 4.92% | 1.73 млн | 2026-06-30 |
| AWM Investment Company,… | 3.3% | 1.16 млн | 2026-06-30 |
| Vanguard Capital Managem… | 2.39% | 839 306 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.32% | 815 192 | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.11% | 742 194 | 2026-08-31 |
| Prospect Capital Advisor… | 1.42% | 497 800 | 2026-06-30 |
| State Street Corporation | 1.21% | 426 004 | 2026-06-30 |
| Geode Capital Management… | 1.15% | 402 566 | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.9% | 316 471 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.78% | 274 781 | 2026-08-31 |
| ANDRADE ROBERT C (Chief… | ≈0.69% | 241 306 | 2026-08-31 |
| Jane Street Group, LLC | 0.67% | 233 877 | 2026-06-30 |
| VANGUARD SCOTTSDALE FUND… | 0.42% | 149 156 | 2026-05-31 |
| RAYKOV ROSTISLAV CHRISTO… | ≈0.35% | 124 411 | 2026-09-01 |
| Bridgeway Funds, Inc.-Ul… | 0.31% | 108 005 | 2026-06-30 |
| iShares Trust-iShares Mi… | 0.28% | 98 294 | 2026-08-31 |
| College Retirement Equit… | 0.24% | 85 124 | 2026-06-30 |
| SCHWAB CAPITAL TRUST-Sch… | 0.2% | 70 504 | 2026-07-31 |
| HACKMAN JEFFREY S (Chief… | ≈0.19% | 67 461 | 2026-09-30 |
| RALLIS CHRISTOPHER ANIGE… | ≈0.18% | 63 077 | 2026-05-11 |
| Quantitative Master Seri… | 0.14% | 50 481 | 2026-06-30 |
| CIOFFI CHRISTIANA MARIE… | ≈0.07% | 24 644 | 2026-08-31 |
| EVANS TERRY L (Officer) | ≈0.06% | 21 687 | 2026-09-30 |
| SAYAD PIERRE SARGIS PH.D… | ≈0.03% | 9 687 | 2026-09-30 |
| BRUGHERA MARCO MARIA (Di… | — | 0 | 2026-09-15 |
| SOUTHPOINT CAPITAL ADVIS… | — | — | 2025-12-24 |
